Witzig T E, Gertz M A, Pineda A A, Kyle R A, Greipp P R
Division of Internal Medicine and Hematology, Mayo Clinic, Rochester, MN 55905.
Br J Haematol. 1995 Mar;89(3):640-2. doi: 10.1111/j.1365-2141.1995.tb08378.x.
We evaluated the harvest product from 47 patients undergoing peripheral blood (BP) stem cell collections for monoclonal plasma cells (PC) using a sensitive immunofluorescence technique. 60% (28/47) had documented tumour cells in the apheresis product. The 32 patients in plateau had a mean of 1.62 x 10(6) PC/l v 74.64 x 10(6) in 15 relapsed patients (P < 0.01). 32% (6/19) of patients without any tumour cells in the initial sample had them detected on a subsequent apheresis sample. In four cases (all treated with GM-CSF) small numbers of tumour cells were detected initially but became undetectable on a subsequent sample.
我们使用一种灵敏的免疫荧光技术,对47例接受外周血(BP)干细胞采集以获取单克隆浆细胞(PC)的患者的采集产物进行了评估。60%(28/47)的患者在单采产物中有记录到肿瘤细胞。处于平台期的32例患者的PC均值为1.62×10⁶/升,而15例复发患者的均值为74.64×10⁶(P<0.01)。初始样本中无任何肿瘤细胞的患者有32%(6/19)在随后的单采样本中检测到了肿瘤细胞。在4例患者中(均接受粒细胞巨噬细胞集落刺激因子治疗),最初检测到少量肿瘤细胞,但在随后的样本中变得无法检测到。